Hair and scalp evidence
What the literature supports for each formulation class
A hair and scalp protocol draws on formulation classes with very different evidence behind them, from an FDA-approved oral label to follicle culture and small early trials. These references take each class on its own terms: what the studies were, what they reported, and what the regulators have said, with the study design labelled beside every citation.
Written for licensed practitioners and practice operators. Two product regimes appear here and never mix: exosome material is supplied for research use, and compounded scalp formulations are 503A prescription products. Neither is FDA-approved for hair loss.
References
4 of 9 published. The remainder are in review and will appear as they are completed.
The Hair Follicle Cycle and the Levers a Protocol Acts On
The cycle, the dermal papilla, and the four levers.
In review
Finasteride: Mechanism, Approved Label, and Topical Literature
The oral label, the topical literature, and the FDA alert.
Minoxidil, Minoxidil Sulfate, and Follicular Sulfotransferase
The prodrug, the enzyme, and the combinations.
GHK-Cu in Follicle and Dermal Papilla Research
Follicle culture, animal models, and the regulatory position.
Extracellular Vesicles and Dermal Papilla Signalling
The human evidence to date, the registry, and the FDA communications.
Ketoconazole and Azelaic Acid in Scalp Research
The shampoo studies and the in vitro work.
In review
Vitamin D, Biotin, Thyroid and Sex Steroids in Hair Shedding
Deficiency states, endocrine context, and the biotin assay notice.
In review
Microneedling, PRP and Topical Anaesthesia in Scalp Protocols
The microneedling literature and the anaesthetic formulations.
In review
FDA Communications Relevant to Hair Products
The finasteride alert, the exosome notification, and the biotin notice.
In review
This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. The FDA has not approved GHK-Cu or any exosome product for hair loss or any form of alopecia. Compounded medications are not FDA-approved; they are prepared by a licensed 503A compounding pharmacy for an individual patient against that patient’s prescription, and they are supplied to NPI-verified licensed practitioners only. Where this page discusses an FDA-approved active such as oral finasteride or topical minoxidil, the approved product’s labeling governs and nothing here modifies it. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. ExaVeyra Sciences does not supply controlled substances. Findings described on this page are attributed to the peer-reviewed literature and to the agencies cited, and a citation establishes that a question was studied, not that any product is suitable for a given patient. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.